If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

PFIZi018-A

BC143c8, RCi207

iPSC line

Not-for-profit fee: £1400 per vial
Immediately available for distribution*
*Once all legal and processing details completed
Timepoint: 48hr post thaw
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Timepoint: Confluency
Magnification: x4
Timepoint: Confluency
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name PFIZi018-A
Alternative name(s)
BC143c8, RCi207
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
PFIZi009-A
(RCi188)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi015-A
(OD003-s5)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi016-A
(OD005-s9)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi017-A
(BC142c7, RCi209)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi019-A
(RCi202, BC145c6)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi014-A
(OD002-s7)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi021-A
(OD001-s7)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome

Provider

Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC

External Databases

hPSCreg PFIZi018-A
BioSamples SAMEA4458850
Cellosaurus CVCL_RF97
Wikidata Q54947273

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no

Donor Information#

General Donor Information

Sex female
Age of donor (at collection) 10-14

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMEI
  • Severe myoclonus epilepsy of infancy
  • Severe myoclonic epilepsy of infancy
Genetic variants
SCN1A (target)
2q24.3
NM_001165963.1:c.3733C>T
Heterozygous
Transition C > T, Nucleotide position 3733, codon 1245, Amino Acid Change Arginine > OPA, Variant Type: heterozygous
Disease associated phenotypes
  • Tonic-clonic seizures
  • Memory: Recent and remote memory are reduced
  • Attention/Concentration: Impaired
  • Judgement/Fund of Knowledge: Reduced
  • Normal station and gait

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4458851

hIPSC Derivation#

General

Source cell type
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
  • normoblast
Age of donor (at collection) 10-14

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium Essential 8
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 21
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
TRA 1-60
Yes
SSEA-4
Yes
SSEA-1
No
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SOX17
Yes
GATA6
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
NCAM1
Yes
VIM
Yes
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
NeuroD1
Yes
HES5
Yes
PAX6
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No autosomal or sex chromosome aneuploidies were detected
Passage number: 40
Karyotyping method: KaryoLite BoBs

Other Genotyping (Cell Line)